Good news for those with diffuse large B-cell lymphoma (DLBCL):”Regeneron and Zai Lab to develop and commercialize REGN1979 in China”

Regeneron Presents Positive Data on Lymphoma Candidate: Regeneron announced positive early-stage data for pipeline candidate, REGN1979. The data will be presented at the 24th Congress of the European Hematology Association (EHA). REGN1979, an investigational bispecific monoclonal antibody, is being evaluated in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The data also includes patients with R/R diffuse large B-cell lymphoma (DLBCL), who had progressed after CAR-T therapy. The primary objective was to assess the safety, tolerability and dose-limiting toxicities of the candidate. High response rates observed with REGN1979 in both relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma were encouraging. Moreover, two patients, who failed CAR-T therapy and received REGN1979 80 mg, achieved complete response.

The R/R follicular lymphoma (FL) grades 1 to 3a treatment arm showed an overall response rate of 93% (13 of 14 patients) in patients, who received doses of 5 mg or more, with a complete response rate of 71% (10 of 14 patients). In DLBCL patients treated with REGN1979 80 mg to 160 mg, an overall response rate of 57% was observed. In R/R DLBCL patients, whose disease progressed after CD-19 directed CAR-T therapy, two out of four achieved a complete response.The company will initiate a phase II program later in the month for a potential registration, and proactively evaluate active REGN1979 doses in indolent and aggressive non-Hodgkin lymphoma.

These response rates show great promise, new hope and further clinical trials are in the works. At University of California Irvine they are recruiting patients:

Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies

If you have a diagnosis of DLBCL you may be a candidate to get the treatment. It is a “safety and tolerability” trial, so this is very early in the process. Any patient can contract the Clinical Trial and see if they qualify. There is no cost, and there is no harm in asking. Contact:

Contact: Clinical Trials Administratorclinicaltrials@regeneron.com

To get more information. Here are cancer centers that you could go to:

Hawaiʻi residents would probably choose Stanford or UCI.

It never hurts to check out a Clinical Trial just in case you need urgent access to a new and promising treatment. Clinical Trials are free except that _ for Hawaiʻi residents _ travel costs may be yours to pay.

Roundup has been known to cause DLBCL, and so if you also had a job that exposed you to Roundup, you may be entitled to hold Roundup responsible for your illness and recover money damages that could help you get treatments that your insurance won’t pay for. The manufacturer knew of the cancer-causing power of Round-up but chose huge profits over people’s lives.

Being proactive about health is the best way to thrive, and survive.